Security Snapshot

Definium Therapeutics, Inc. - Common Shares, no par value per share (DFTX) Institutional Ownership

CUSIP: 24477V105

13F Institutional Holders and Ownership History from Q4 2025 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

8

Shares (Excl. Options)

11,252,538

Price

$13.39

Type / Class
Equity / Common Shares, no par value per share
Symbol
DFTX on Nasdaq
Shares outstanding
103,177,431
Price per share
$18.95
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
11,252,538
Total reported value
$150,679,840
% of total 13F portfolios
0%
Share change
+11,252,147
Value change
+$150,673,017
Number of holders
8
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • DFTX - Definium Therapeutics, Inc. - Common Shares, no par value per share is tracked under CUSIP 24477V105.
  • 8 institutions reported positions in Q4 2025.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 8 to 4 between Q4 2025 and Q1 2026.
  • Reported value moved from $150,679,840 to $35,337.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Official SEC Source

Backed by Form 13F

Ownership context comes from SEC Form 13F and, when available, Schedule 13D/13G filings.

See Original Filing

Investment Quick Answers

What is CUSIP 24477V105?
CUSIP 24477V105 identifies DFTX - Definium Therapeutics, Inc. - Common Shares, no par value per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Definium Therapeutics, Inc. - Common Shares, no par value per share (DFTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Commodore Capital LP 7.2% 7,428,775 Commodore Capital LP 31 Dec 2025
DRIEHAUS CAPITAL MANAGEMENT LLC 6.6% 6,537,202 DRIEHAUS CAPITAL MANAGEMENT LLC 31 Dec 2025
Deep Track Capital, LP 5.5% 5,676,540 Deep Track Capital, LP 31 Dec 2025
Avoro Capital Advisors LLC 5.1% 5,000,000 Avoro Capital Advisors LLC 31 Dec 2025

As of 31 Dec 2025, 8 institutional investors reported holding 11,252,538 shares of Definium Therapeutics, Inc. - Common Shares, no par value per share (DFTX). This represents 11% of the company’s total 103,177,431 outstanding shares.

Top 8 Institutional Shareholders

The largest institutional shareholders of Definium Therapeutics, Inc. - Common Shares, no par value per share (DFTX) together control 11% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Driehaus Capital Management LLC 6.3% 6,537,202 0.59% $87,533,135
MARSHALL WACE, LLP 2.9% 2,975,702 0.04% $39,844,652
AWM Investment Company, Inc. 1.3% 1,390,662 1.8% $18,620,964
Ensign Peak Advisors, Inc 0.25% 262,000 0.01% $3,508,180
PRICE T ROWE ASSOCIATES INC /MD/ 0.05% 52,230 0% $700,000
DARK FOREST CAPITAL MANAGEMENT LP 0.03% 30,661 0.02% $410,551
Sound Income Strategies, LLC 0% 3,690 0% $55,535
Sankala Group LLC 0% 391 0% 0.01% $6,823

Institutional Holders of Definium Therapeutics, Inc. - Common Shares, no par value per share (DFTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 1,824 $35,337 +$28,227 $18.95 4
2025 Q4 11,252,538 $150,679,840 +$150,673,017 $13.39 8

Sponsored